LifeVantage Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue fell 25.2% year-over-year due to lower MindBody GLP-1 sales, with adjusted EBITDA and net income also declining. Americas saw a notable drop in consultant count, but the company remains debt-free, increased its dividend, and expects full-year results near the low end of guidance.
-
The session highlighted a transformation from retail to direct sales, a rigorous five-pillar approach to product development, and a strong focus on nutrigenomics. With robust financials, international expansion, and an 18-month innovation cadence, significant growth is anticipated.
-
The company highlighted strong financials, robust product innovation, and successful integration of a recent acquisition. Growth is expected from international expansion, new product launches, and digital investments, while a CEO succession plan is in progress.
-
Q2 revenue fell 27.8% year-over-year, mainly due to MindBody GLP-1 sales declines amid increased competition from pharmaceuticals, but sequential growth and LoveBiome integration provided some offset. A $2.4M inventory reserve was taken, and a new $60M share repurchase program was announced.
-
The company is advancing its activation-based product strategy, highlighted by a successful acquisition in the gut health space and rapid integration of new consultants. Investments focus on technology and international expansion, while a revamped compensation plan attracts a broader range of sellers.
-
Q1 2026 revenue rose 0.7% to $47.6M, with adjusted EBITDA at $3.9M and net income at $2.3M. The LoveBiome acquisition was completed and fully integrated, expanding the addressable market. Full-year revenue is guided at $225M–$240M, with stronger growth expected in the second half.
Fiscal Year 2025
-
The company completed the LoveBiome acquisition, integrated consultants, and launched a synergistic product stack. Scientific studies showed strong results for P84, and international expansion resumed with Iceland. Focus areas for 2026 include subscriptions, e-commerce, and further global growth.
-
Direct sales operations focus on 'activation' health products, with 70% recurring revenue and strong U.S. presence. Recent acquisition of LoveBiome expands into gut health, while new compensation plans attract micro-influencers. Growth is driven by innovation, platform upgrades, and international expansion.
-
The company highlighted strong FY 2025 results, driven by innovative health products and a robust direct sales model. Recent acquisition of LoveBiome and continued product innovation support growth, while a balanced capital allocation strategy and high subscription revenue ensure financial strength.
-
Fourth quarter revenue rose 12.6% year-over-year to $55.1 million, with margin expansion and strong Americas and international growth. The acquisition of LoveBiome and a new Shopify partnership are set to drive further growth, with fiscal 2026 revenue guidance of $225–$240 million.
-
MindBody GLP-1 System continues to drive strong sales growth and delivers clinically validated benefits beyond weight loss. International expansion is progressing well, with localized strategies and incentives to boost growth. Margins are expected to improve, and capital allocation remains flexible with increased dividends and potential share repurchases.
-
Third-quarter revenue grew 21% year-over-year to $58.4 million, led by strong U.S. demand for the MindBody GLP-1 system, while international sales declined. Gross margin improved to 81%, and adjusted EBITDA rose 27%. Fiscal 2025 revenue is projected to increase 16% at the midpoint.
-
Q2 revenue surged 44% sequentially and 31% year-over-year, driven by the MindBody GLP-1 System launch, with gross margin up 190 bps and adjusted EBITDA more than doubling. Americas growth offset international declines, and FY25 guidance was raised for revenue and EBITDA.
-
A natural GLP-1 product launch drove record demand, rapid sellouts, and a 30% revenue increase, prompting higher annual guidance. The company modernized its compensation plan to attract social sellers and influencers, fueling new customer growth and higher subscription rates.
-
First quarter revenue declined 8.1% year-over-year, but adjusted EBITDA rose 11% as the MindBody GLP-1 System launch drove record demand and rapid stockout. Fiscal 2025 guidance remains unchanged, with optimism for the upper end of the range due to strong product momentum.
Fiscal Year 2024
-
A new GLP-1-based supplement drove record demand, selling out rapidly and prompting a global rollout. Strong clinical results and consultant excitement are fueling growth, with international launches and a unified compensation plan set for 2025.
-
Recent product launches, especially the GLP-1 weight management system, have driven record enrollments and sales, with strong clinical results and a focus on long-term lifestyle benefits. The company maintains a robust financial position, is expanding internationally, and has returned over $50M to shareholders in six years.
-
Q4 FY2024 saw strong profitability with a 9.8% Adjusted EBITDA margin, despite a 10% revenue decline. Sequential improvements in active accounts and consultant productivity were noted, and a new GLP-1 weight management product will launch in October.